Randomized Trialvery high evidence
Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial.
Lancet (London, England)·February 10, 2024·PMID 38310910
Why it mattersR21/Matrix-M is a low-cost, high-efficacy malaria vaccine that has received WHO prequalification. This trial provides robust evidence supporting its use in routine childhood immunization programs across diverse malaria transmission settings in sub-Saharan Africa.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled